250 related articles for article (PubMed ID: 27813130)
1. P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
Deshmukh RR; Kim S; Elghoul Y; Dou QP
J Cell Biochem; 2017 May; 118(5):1239-1248. PubMed ID: 27813130
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy.
Uddin MM; Zou Y; Sharma T; Gatla HR; Vancurova I
PLoS One; 2018; 13(8):e0201858. PubMed ID: 30089134
[TBL] [Abstract][Full Text] [Related]
3. Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.
Shi Y; Yu Y; Wang Z; Wang H; Bieerkehazhi S; Zhao Y; Suzuk L; Zhang H
Oncotarget; 2016 Nov; 7(45):73697-73710. PubMed ID: 27655642
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Zang Y; Kirk CJ; Johnson DE
Cancer Biol Ther; 2014 Sep; 15(9):1142-52. PubMed ID: 24915039
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
Chen YJ; Yeh MH; Yu MC; Wei YL; Chen WS; Chen JY; Shih CY; Tu CY; Chen CH; Hsia TC; Chien PH; Liu SH; Yu YL; Huang WC
Breast Cancer Res; 2013 Nov; 15(6):R108. PubMed ID: 24216290
[TBL] [Abstract][Full Text] [Related]
6. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
7. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.
Weyburne ES; Wilkins OM; Sha Z; Williams DA; Pletnev AA; de Bruin G; Overkleeft HS; Goldberg AL; Cole MD; Kisselev AF
Cell Chem Biol; 2017 Feb; 24(2):218-230. PubMed ID: 28132893
[TBL] [Abstract][Full Text] [Related]
9. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
10. Combination of Second-Generation Proteasome Inhibitor Carfilzomib with Bortezomib in Four Different Breast Cancer Cell Lines.
Altundag EM; Yilmaz AM; Sahin A; Yilmaz BK
Anticancer Agents Med Chem; 2022 Aug; 22(16):2909-2918. PubMed ID: 35352669
[TBL] [Abstract][Full Text] [Related]
11. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
Lee JO; Kang MJ; Byun WS; Kim SA; Seo IH; Han JA; Moon JW; Kim JH; Kim SJ; Lee EJ; In Park S; Park SH; Kim HS
Breast Cancer Res; 2019 Oct; 21(1):115. PubMed ID: 31640742
[TBL] [Abstract][Full Text] [Related]
12. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
[TBL] [Abstract][Full Text] [Related]
14. Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis.
Liu L; Fu Y; Zheng Y; Ma M; Wang C
Phytomedicine; 2020 Nov; 78():153312. PubMed ID: 32866906
[TBL] [Abstract][Full Text] [Related]
15. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
[TBL] [Abstract][Full Text] [Related]
16. Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.
Muz B; Kusdono HD; Azab F; de la Puente P; Federico C; Fiala M; Vij R; Salama NN; Azab AK
Leuk Lymphoma; 2017 Dec; 58(12):2916-2925. PubMed ID: 28509582
[TBL] [Abstract][Full Text] [Related]
17. RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma.
Gu C; Lu T; Wang W; Shao M; Wei R; Guo M; Li R; Qiao L; Hu Y; Zhan F; Seckinger A; Hose D; Yang Y
Leukemia; 2021 Jun; 35(6):1803-1807. PubMed ID: 32901100
[No Abstract] [Full Text] [Related]
18. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Gohr K; Hamacher A; Engelke LH; Kassack MU
BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
[TBL] [Abstract][Full Text] [Related]
20. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
